Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1991-09-18
1998-10-13
Stucker, Jeffrey
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4242081, 530326, 530327, A61K 3921
Patent
active
058208658
ABSTRACT:
The instant invention describes the synthesis of short peptides, corresponding to the amino acid residues of the V3 loop of the gpl6O envelope glycoprotein of HIV-1 numbered 315 to 329 by Ratner (Ratner, L. et al., Nature 313, 277 (1985)) in the strain IIIB, wherein the residue corresponding to number 325 in HIV-1 IIIB is substituted by the homologous residue from another clinical isolate or strain. The invention further describes the use of said peptides in pharmaceutical compositions and an immunization protocol which elicits cytotoxic T cells reactive to a broad range of isolates of HIV-1.
REFERENCES:
patent: 5562905 (1996-10-01), Kenealy et al.
H. Takahashi et al. Proc. Natl. Acad Sci. USA 85:3105 (1988).
H. Takahashi et al, Science 246:118 (1989).
H. Takahashi et al, J.Exp.Med. 170:2023 (1989).
H. Takahashi et al, Nature 334:873 (1990).
Takahashi, H. et al., Science, 246:118-121, 1989.
Neuroth, A.R. et al. "Confronting the Hypervaribility of an Immunodominant Epitope Eliciting Virus Neutralizing Antibodies from the Envelope Glycoprotein of the Human Immunodeficiency Virus type 1(HIV 1)". Mol. Immun. vol. 27, No. 6 pp. 539-549, 1990.
Takahashi, Hidemi et al. "A Single Amino Acid Interchange Yields Reciprocal CTL Specificities of HIV-1 gp160", Science 10/6/1989. vol. 246 pp. 118-121.
Klinman, Dennis M. et al "Sequential Immunizations with rgp 120;from Independent Isolates of HIV-1 Induce the Preferential Expansion of Broadly Crossreactive B Cells." J. Exp. Med. vol. 173, Apr. 91 pp. 881-887.
Nari, Peter et al "Clonal Dominance of the Neutralizing Response to the HIV-1 V-3 Epitope: Evidence for Original Antigenic Sin during Vaccination and Infection on Animal, Including Humans" Vaccines 91 pp. 881-887. Cold Spring Harbor lab.
Weinhold, Kent et al "Human T-cell Clones Define Distinct Epitopes Within the V-3 Region of HIV-1 gp120". V Int. Conf. on AIDS, Montreal Jun. 4-9 1989. 545.
Fultz, P.N. et al "Infection of Non-human Primates with Human and Simian Immunodeficiency Viruses." AIDS Vaccine Research and Clinical Trials. Putney SD& Bolognesi DP editors. NY, 1990. pp. 339-349. Abstract.
Hileman MR. "Conclusions: In Pursuit of an AIDS Virus Vaccine" Abstract. Immunol. Ser. 44:605-620. 1989.
Eichberg, J.W. Experience with 13 HIV Efficiency trials on Chimpanzees. Int Conf. on AIDS Jun. 20-23,1990, 6 (1) p. 204. Abstract # Th.A.338.
Fauci, AS et al. "Development and evaluation of a Vaccine for HIV infection" Ann Intern. Med. Mar. 1, 1989. 110 (5) pp. 373-385.
Vacolio et al. Sequences Outside A Minimal Immundominant Site Exert Negative Effects on Recognition By Staphylococcal.
Nuclease-Specific T-Cell Clones J. of Immunol. vol. 143, No. 9, Nov. 1, 1989, pp. 2814-2819.
Kumar et al. "Amino-acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation . . . allergic encephalomyelitis" PNAS 87, Feb. 1990 pp. 1337-1341.
LaRosa et al. "Conserved Sequence & Structural Elements in the HIV-1 Principal Neutralizing Determinant" Science V.249 24 Aug. 1990, pp. 932-935.
Rusche et al. "Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120".
PNAS vol. 85, May 1988, pp. 3198-3202.
Javaherian et al. "Principal neutralizing domain of the human immunodeficiency type 1 envelope protein".
PNAS vol. 86, Sep. 1989, pp. 6768-6772.
Berzofsky Jay A.
Germain Ronald N.
Takahashi Hidemi
Stucker Jeffrey
The United States of America as represented by the Department of
LandOfFree
Method to induce cytotoxic T Lymphocytes specific for a broad ar does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to induce cytotoxic T Lymphocytes specific for a broad ar, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to induce cytotoxic T Lymphocytes specific for a broad ar will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-310882